Incretin-mediated control of cardiac energy metabolism
Journal of Endocrinology · 2024
DOI: 10.1530/joe-24-0011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, 2024. Verfasst von Jordan S F Chan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Incretins, Energy Metabolism, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like-peptide-1 (GLP-1) are incretin hormones that stimulate insulin secretion and improve glycemic control in individuals with type 2 diabetes (T2D). Data from several cardiovascular outcome trials for GLP-1 receptor (GLP-1R) agonists have demonstrated significant reductions in the occurrence of major adverse cardiovascular events in individuals with T2D. Although the cardiovascular actions attributed to GLP-1R agonism have been extensively studied, little is known regarding the cardiovascular consequences attributed to GIP receptor (GIPR) agonism. As there is now an increasing focus on the development of incretin-based co-agonist therapies that activate both the GLP-1R and GIPR, it is imperative that we understand the mechanism(s) through which these incretins impact cardiovascular function. This is especially important considering that cardiovascular disease represents the leading cause of death in individuals with T2D. With increasing evidence that perturbations in cardiac energy metabolism are a major contributor to the pathology of diabetes-related cardiovascular disease, this may represent a key component through which GLP-1R and GIPR agonism influence cardiovascular outcomes. Not only do GIP and GLP-1 increase the secretion of insulin, they may also modify glucagon secretion, both of which have potent actions on cardiac substrate utilization. Herein we will discuss the potential direct and indirect actions through which GLP-1R and GIPR agonism impact cardiac energy metabolism while interrogating the evidence to support whether such actions may account for incretin-mediated cardioprotection in T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
- Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
- Cardiovascular Research Institute, University of Alberta, Edmonton, Alberta, Canada.
ORCID-Profile: Jordan S F Chan, John R Ussher
Zitieren
APA
Chan, J. S. F., Shafaati, T., & Ussher, J. R. (2024). Incretin-mediated control of cardiac energy metabolism. Journal of Endocrinology. https://doi.org/10.1530/joe-24-0011
Vancouver
Chan JSF, Shafaati T, Ussher JR. Incretin-mediated control of cardiac energy metabolism. Journal of Endocrinology. 2024. doi:10.1530/joe-24-0011
BibTeX
@article{Chan2024,
author = {Chan, Jordan S F and Shafaati, Tanin and Ussher, John R},
title = {Incretin-mediated control of cardiac energy metabolism},
journal = {Journal of Endocrinology},
year = {2024},
doi = {10.1530/joe-24-0011}
}
EUVIMED